Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
17.89
+1.35 (8.16%)
Mar 31, 2026, 4:00 PM EDT - Market closed
Aktis Oncology Revenue
In the year 2025, Aktis Oncology had annual revenue of $6.50M with 336.92% growth. Aktis Oncology had revenue of $1.87M in the quarter ending December 31, 2025.
Revenue (ttm)
$6.50M
Revenue Growth
+336.92%
P/S Ratio
144.62
Revenue / Employee
$85,487
Employees
76
Market Cap
939.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.50M | 5.01M | 336.92% |
| Dec 31, 2024 | 1.49M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAKTS News
- 1 day ago - Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Aktis Oncology to Present at Upcoming March Investor Conferences - GlobeNewsWire
- 5 weeks ago - Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate - GlobeNewsWire
- 2 months ago - Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - U.S. IPO Weekly Recap: Aktis Oncology Leads As First Sizable 2026 IPO - Seeking Alpha
- 2 months ago - Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets - Business Wire
- 2 months ago - Aktis Oncology prices upsized US IPO at $18 per share - Reuters
- 2 months ago - Aktis Oncology Announces Pricing of its Upsized Initial Public Offering - GlobeNewsWire